MBP 3.23% 3.0¢ metabolic pharmaceuticals limited

sanity will prevail, page-4

  1. 131 Posts.
    gabothegreat been a memer for 1 week?
    someone has misunderstood the statistics
    this is phase 2b not phase 3 of the trial and hence the small no. of patients in the trial.
    the aim of the trial was to assess safety and tolerablity and weight loss and fat loss. This was not a phase 3 pivotal trial. For each of the primary endpoints (aims) the trial was positive. To answer definitively the question whether the drug is effective requires a phase 3 trial with sufficient numbers for the statistics to then be significant
    The results of this phase 2b trial more than justify proceeding to a phase 3 pivotal trial
 
watchlist Created with Sketch. Add MBP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.